Erythema nodosum leprosum: Clinical and therapeutic up-date;Eritema nodoso hansênico: Atualização clínica e terapêutica

Anais Brasileiros de Dermatologia

Volumn 77, Issue 4, 2002, Pages 389-405

  Guerra, Jackeline Gomes ^a   Miranda de Castro, Lia Cândida ^a   Araújo Stefani, Mariane Martins ^a   Penna, Gerson Oliveira ^a   Turchi Martelli, Celina Maria ^a  

^a NONE   (Brazil)

Author keywords

Erythema nodosum; Leprosy

Indexed keywords

ANALGESIC AGENT; CLOFAZIMINE; CORTICOSTEROID; CYTOKINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PREDNISONE; STEROID; THALIDOMID; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

BRAZIL; CHRONIC DISEASE; CORTICOSTEROID THERAPY; DISEASE COURSE; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG SURVEILLANCE PROGRAM; ENDEMIC DISEASE; ERYTHEMA NODOSUM LEPROSUM; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; IMMUNOPATHOGENESIS; IRITIS; LEPROSY; LEPROSY CONTROL; MORBIDITY; MYCOBACTERIUM LEPRAE; NERVE INJURY; ORCHITIS; PARALYSIS; PERIPHERAL NEUROPATHY; REVIEW; STEROID THERAPY; SYNDROME; TERATOGENICITY;

EID: 0346062160     PISSN: 03650596     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Classification of leprosy according to immunity. A five-group system
2. Hanseníase: Aspectos clínicos, imunológicos e terapêuticos
3. Letter to the editor
4. Leprosy - Global situation
5. Mycobacterium leprae - Millennium resistant! Leprosy control on the threshold of new era
6. Hanseníase
7. Leprosy at a taming point?
8. Clinical leprosy
9. Joint chemotherapy trials in lepromatous leprosy conducted in Thailand, The Philippines and Korea
10. Risk factors for erythema nodosum leprosum
11. Chemotherapeutic trials in leprosy
12. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control of the all Africa leprosy and rehabilitation training center (ALERT) in Ethiopia
13. ENL reactions in the multibacillary cases of the AMFES cohort in central Ethiopia: Incidence end risk factors
14. Incidence of late lepra reaction among multibacilary leprosy patients after MDT
15. Leprosy reactions
16. Epidemiological characteristics of leprosy reactions
17. Características clínico-histopatológicas dos estados reacionais na Hanseníase em pacientes submetidos à poliquimioterapia
18. Erythema nodosum in leprosy
19. Pregnancy and Leprosy: A comprehensive literature review
20. Leprosy and pregnancy: A study of reactional states
21. A study of 250 patients in a multidrug therapy project, Baroda district, Gujarat, India
22. Reactions in Leprosy - A prospective study of clinical, bacteriological, immunological and histopathological parameters in thirty-five Indians
23. Prospective study on the relationship between intensive bactericidal therapy and leprosy reactions
24. Potenciais implicações da co-infecção HIV e Mycobacterium leprae em saúde pública
25. Réactions lépreuses
26. Erythema nodosum type of lepra reaction
27. Erythema nodosum in leprosy
28. Recurrent erythema nodosum leprosum precipitated by antileprosy drugs
29. Study of erythrocyte G-6PD deficiency in leprosy
30. HLA antigens and erythema nodosum leprosum
31. Tumor necrosis factor promotor polymorphism and susceptibility to lepromatous leprosy
32. Serum levels of tumor necrosis factor-alpha and interleukin-1b during leprosy reactional states
33. Assessment of anti-PGL-I as a prognostic marker of leprosy reaction
34. Global elimination of leprosy
35. Leprosy reactional states and their treatment
36. Panniculitis. Part I. Mostly septal panniculitis
37. Panniculitis. Part II. Mostly lobular panniculitis
38. Erythema nodosum leprosum: Nature and extent of the cutaneous microvascular alterations
39. Necrotizing reaction in lepromatous leprosy: A clinical and histopathologic study
40. Defining protective responses to pathogens: Cytokines profiles in leprosy lesions
41. Imunologia
42. Immunology of leprosy: Lessons from and for leprosy
43. The effect of antigen presenting cells on the cytokine profiles of stable and reactional lepromatous leprosy patients
44. Manifestações sistêmicas
45. Erythema nodosum leprosum: A clinical manifestation of Arthus phenomenon
46. Renal manifestation of leprosy: Glomeronephritis, a complication of erythema nodosum leprosum
47. Immune complexes and complement hypercatabolism in patients with leprosy
48. Changes in circulating antibody levels to the major phenolic glycolipid during erythema nodosum leprosum in leprosy patients
49. Mechanisms of reaction in leprosy
50. Cytokine patterns of immunologically mediated tissue damage
51. Erythema nodosum leprosum
52. Imbalances in T cell subpopulations in lepromatous leprosy
53. Thymus dependent lymphocytes in leprosy: I. T lymphocyte subpopulations defined by monoclonal antibodies
54. Tissue and blood T-Lymphocyte subpopulations in erythema nodosum leprosum
55. Expression and cytokine secretion in the states of immune reactivation in leprosy
56. Lepromatous leprosy pacients show T helper 1-like cytokine profile with differencial expression of interleukin-10 during type 1 and 2 reactions
57. Dysregulation of IL-4 expression in lepromatous leprosy patients with and without erythema nodosum leprosum
58. Effect of rhu IFN-gamma treatment in multybacilary leprosy patients
59. Cytokines in leprosy, I. Serum cytokine profile in leprosy
60. Immunological status of ENL (erythema nodosum leprosum) patients: Its relationship to bacteria load levels of circulating IL-2R
61. IgG antibody subclasses, tumor necrosis factor and INF-g levels in patients with type II lepra reaction on thalidomide treatment
62. Tumor necrosis factor production in patients with leprosy
63. Correlation between TNF, increase of plasma C-reative protein level and supression of T lymphocyte response to concavalin A during erythema nodosum leprosum
64. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
65. Talidomida: Mecanismo de ação, efeitos colaterais e uso terapêutico
66. Ministério da Saúde
67. Glucocorticoid therapy for immune-mediated diseases: Basic and clinic correlates
68. Thalidomide in the treatment of lepra reactions
69. Tratamento da reação leprótica pela talodomida
70. Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy
71. Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood
72. Studies on the mechanism of action of thalidomide in leprosy
73. Talidomida: Uma medicação eclética em dermatologia
74. In Relatório da contribuição da Sociedade Brasileira de Dermatologia (SBD) à Portaria Ministerial n 1.377 de 15 de dezembro de 2000
75. Leprosy
76. Is Pentoxifyline a viable alternative in the treatment of ENL?
77. Pentoxifiline may be useful in the treatment of type 2 leprosy reaction
78. A new therapeutic approach to type II leprosy reaction
79. Potential of thalidomide and thalidomide analogues as immunomodulatory drugs in leprosy and leprosy reactions